A meta-analysis on the safety of combination therapy with fenofibrate and statins / 中华心血管病杂志
Chinese Journal of Cardiology
;
(12): 1063-1068, 2013.
Artículo
en Chino
| WPRIM
| ID: wpr-356454
ABSTRACT
<p><b>OBJECTIVE</b>The aim of this study was to assess the safety of fenofibrate-statin combination therapy.</p><p><b>METHODS</b>Medline, Cochrane Library, Web of Knowledge and CNKI were searched for 2184 randomized controlled trials. Finally, twenty-six studies with a total of 9494 participants were included in this analysis.</p><p><b>RESULTS</b>Compared with statins group, the fenofibrate-statin group had significantly higher incidence of aminotransferase elevations (OR 1.67, 95%CI 1.22-2.30, P < 0.05) . The two groups had identical incidence of creatin kinase elevations (OR 0.86, 95%CI 0.62-1.20, P > 0.05) , muscle-associated adverse events (OR 0.98, 95%CI 0.88-1.09, P > 0.05) and withdrawals due to hepatotoxicity or muscle toxicity. The safety of fenofibrate + standard-dose statin regimens were similar to those in fenofibrate-statin group.</p><p><b>CONCLUSION</b>Combined fenofibrate-statin treatment is generally safe and well tolerated, liver function should be monitored before and during and after therapy.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fenofibrato
/
Ensayos Clínicos Controlados Aleatorios como Asunto
/
Terapia Combinada
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Usos Terapéuticos
/
Hipolipemiantes
Tipo de estudio:
Ensayo Clínico Controlado
/
Revisiones Sistemáticas Evaluadas
Límite:
Adulto
/
Anciano
/
Aged80
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Chinese Journal of Cardiology
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS